Intra-Cellular Therapies Inc ITCI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
-
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
-
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
-
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
-
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
-
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
Trading Information
- Previous Close Price
- $73.21
- Day Range
- $72.54–74.62
- 52-Week Range
- $45.50–84.89
- Bid/Ask
- $71.92 / $74.73
- Market Cap
- $7.75 Bil
- Volume/Avg
- 385,517 / 867,756
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 561
Comparables
Valuation
|
Metric
|
ITCI
|
UTHR
|
AVIR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 18.27 | — |
Price/Book Value | 6.76 | 2.80 | 0.61 |
Price/Sales | 12.78 | 6.74 | — |
Price/Cash Flow | — | 14.46 | — |
Price/Earnings
ITCI
UTHR
AVIR
Financial Strength
|
Metric
|
ITCI
|
UTHR
|
AVIR
|
|---|---|---|---|
Quick Ratio | 7.22 | 3.92 | 18.87 |
Current Ratio | 7.81 | 4.35 | 19.02 |
Interest Coverage | — | 22.67 | — |
Quick Ratio
ITCI
UTHR
AVIR
Profitability
|
Metric
|
ITCI
|
UTHR
|
AVIR
|
|---|---|---|---|
Return on Assets (Normalized) | −4.42% | 16.95% | −23.62% |
Return on Equity (Normalized) | −5.28% | 20.53% | −25.11% |
Return on Invested Capital (Normalized) | −8.32% | 16.62% | −29.21% |
Return on Assets
ITCI
UTHR
AVIR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Ljkywlzxvp | Kphp | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Sfrtjdvyp | Dyvjhk | $78.0 Bil | |||
| Haleon PLC ADR
HLN
| Dwcvsjpg | Rshlz | $48.4 Bil | |||
| Viatris Inc
VTRS
| Dmsmqbvpl | Ggzsg | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Qntpvxzn | Ylwr | $13.5 Bil | |||
| Catalent Inc
CTLT
| Pqswdbb | Nypwjl | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Kwdfdpjd | Htsyv | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Fjptzwx | Bmlb | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Lwjyktsyj | Ttz | $2.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Ffwzkxxd | Plty | $2.3 Bil |
United States